Tarsus Pharmaceuticals, Inc. TARS Accumulated amortization, debt issuance costs
Accumulated amortization, debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedAmortizationDeferredFinanceCosts.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s accumulated amortization, debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s accumulated amortization, debt issuance costs?
- Tarsus Pharmaceuticals, Inc. (TARS) reported accumulated amortization, debt issuance costs of $1.12M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s accumulated amortization, debt issuance costs changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s accumulated amortization, debt issuance costs increased by 120.9% year-over-year, from $507K to $1.12M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s accumulated amortization, debt issuance costs?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s accumulated amortization, debt issuance costs has grown at a 92.4% compound annual growth rate (CAGR), from $135K to $961K.
- What does accumulated amortization, debt issuance costs mean?
- This represents the cumulative amount of debt issuance costs that have been amortized over the life of the associated debt obligations. It reflects the systematic recognition of financing expenses as they are moved from the balance sheet to the income statement. This metric is used to reconcile the initial costs of securing capital with the ongoing interest expense recognized by the company.